{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:04:11Z","timestamp":1791335051773,"version":"4.3.1"},"reference-count":155,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T00:00:00Z","timestamp":1556064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010198","name":"Ministerio de Econom\u00eda, Industria y Competitividad, Gobierno de Espa\u00f1a","doi-asserted-by":"publisher","award":["PI15\/00255"],"award-info":[{"award-number":["PI15\/00255"]}],"id":[{"id":"10.13039\/501100010198","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010198","name":"Ministerio de Econom\u00eda, Industria y Competitividad, Gobierno de Espa\u00f1a","doi-asserted-by":"publisher","award":["PI16-00723"],"award-info":[{"award-number":["PI16-00723"]}],"id":[{"id":"10.13039\/501100010198","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.00886","type":"journal-article","created":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T04:56:43Z","timestamp":1556081803000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":82,"title":["Nephritic Factors: An Overview of Classification, Diagnostic Tools and Clinical Associations"],"prefix":"10.3389","volume":"10","author":[{"given":"Fernando","family":"Corvillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Okr\u00f3j","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Nozal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Melgosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"S\u00e1nchez-Corral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"L\u00f3pez-Trascasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,4,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3389\/fimmu.2015.00262","article-title":"Complement system part I \u2013 molecular mechanisms of activation and regulation","volume":"6","author":"Merle","year":"2015","journal-title":"Front Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.imbio.2015.05.015","article-title":"Complement genetics and susceptibility to inflammatory disease. lessons from genotype-phenotype correlations","volume":"221","author":"de","year":"2016","journal-title":"Immunobiology."},{"key":"B3","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.semnephrol.2013.08.001","article-title":"Overview of complement activation and regulation","volume":"33","author":"Noris","year":"2013","journal-title":"Semin Nephrol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1038\/ni.3858","article-title":"Novel mechanisms and functions of complement","volume":"18","author":"Hajishengallis","year":"2017","journal-title":"Nat Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00281-017-0663-8","article-title":"Diseases of complement dysregulation-an overview","volume":"40","author":"Wong","year":"2018","journal-title":"Semin Immunopathol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s40620-015-0218-9","article-title":"C3 glomerulonephritis and autoimmune disease: more than a fortuitous association?","volume":"29","author":"Alexander","year":"2016","journal-title":"J Nephrol."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-018-3989-0","article-title":"Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy","author":"Noris","year":"2018","journal-title":"Pediatric Nephrol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nrneph.2016.70","article-title":"Complement in disease: a defence system turning offensive","volume":"12","author":"Ricklin","year":"2016","journal-title":"Nat Rev Nephrol."},{"key":"B9","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1126\/science.164.3878.436","article-title":"Serum C'3 lytic system in patients with glomerulonephritis","volume":"164","author":"Spitzer","year":"1969","journal-title":"Science."},{"key":"B10","doi-asserted-by":"crossref","first-page":"764","DOI":"10.4049\/jimmunol.113.3.764","article-title":"Lysis of human erythrocytes due to activation of the alternate complement pathway by nephritic factor (C3NeF)","volume":"113","author":"Arroyave","year":"1974","journal-title":"J Immunol."},{"key":"B11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4049\/jimmunol.116.1.1","article-title":"C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase","volume":"116","author":"Daha","year":"1976","journal-title":"J Immunol."},{"key":"B12","doi-asserted-by":"crossref","first-page":"812","DOI":"10.4049\/jimmunol.119.3.812","article-title":"The incorporation of C3 nephritic factor (C3NeF) into a stabilized C3 convertase, C3bBb(C3NeF), and its release after decay of convertase function","volume":"119","author":"Daha","year":"1977","journal-title":"J Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3980","DOI":"10.1073\/pnas.74.9.3980","article-title":"Heterogeneity of nephritic factor and its identification as an immunoglobulin","volume":"74","author":"Davis","year":"1977","journal-title":"Proc Natl Acad Sci USA."},{"key":"B14","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/0090-1229(78)90207-6","article-title":"IgG subclass studies of C3 nephritic factor","volume":"11","author":"Davis","year":"1978","journal-title":"Clin Immunol Immunopathol."},{"key":"B15","first-page":"425","article-title":"Identification of nephritic factor as an immunoglobulin","volume":"33","author":"Williams","year":"1978","journal-title":"Clin Exp Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.imlet.2014.01.014","article-title":"Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome","volume":"160","author":"J\u00f3zsi","year":"2014","journal-title":"Immunol Lett."},{"key":"B17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jaci.2017.02.018","article-title":"C3 nephritic factors: a changing landscape","volume":"140","author":"Levy Erez","year":"2017","journal-title":"J Allergy Clin Immunol."},{"key":"B18","first-page":"12","article-title":"The immunogloblin nature of nephritic factor (NeF)","volume":"32","author":"Scott","year":"1978","journal-title":"Clin Exp Immunol."},{"key":"B19","doi-asserted-by":"crossref","first-page":"755","DOI":"10.4049\/jimmunol.123.2.755","article-title":"Further evidence for the antibody nature of C3 nephritic factor (C3NeF)","volume":"123","author":"Daha","year":"1979","journal-title":"J Immunol."},{"key":"B20","first-page":"73","article-title":"Effect of nephritic factor on C3 and on the terminal pathway of complement in vivo and in vitro","volume":"65","author":"Mollnes","year":"1986","journal-title":"Clin Exp Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/0090-1229(89)90141-4","article-title":"A properdin dependent nephritic factor slowly activating C3, C5, and C9 in membranoproliferative glomerulonephritis, types I and III","volume":"50","author":"Clardy","year":"1989","journal-title":"Clin Immunol Immunopathol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/0090-1229(90)90144-F","article-title":"Two types of C3 nephritic factor: properdin-dependent C3NeF and properdin-independent C3NeF","volume":"56","author":"Tanuma","year":"1990","journal-title":"Clin Immunol Immunopathol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S0272-6386(12)81018-3","article-title":"Patterns of complement activation in idiopathic membranoproliferative glomerulonephritis, types I, II, and III","volume":"16","author":"Varade","year":"1990","journal-title":"Am J Kidney Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.kint.2017.04.017","article-title":"C5 nephritic factors drive the biological phenotype of C3 glomerulopathies","volume":"92","author":"Marinozzi","year":"2017","journal-title":"Kidney Int."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/ki.2012.250","article-title":"Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation","volume":"82","author":"Paix\u00e3o-Cavalcante","year":"2012","journal-title":"Kidney Int."},{"key":"B26","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1073\/pnas.73.9.3268","article-title":"Control of the amplification convertase of complement by the plasma protein beta1H","volume":"73","author":"Weiler","year":"1976","journal-title":"Proc Natl Acad Sci USA."},{"key":"B27","first-page":"449","article-title":"Effect of decay-accelerating factor on the assembly of the classical and alternative pathway C3 convertases in the presence of C4 or C3 nephritic factor","volume":"68","author":"Ito","year":"1989","journal-title":"Immunology."},{"key":"B28","first-page":"209","article-title":"Regulation of the C3 nephritic factor stabilized C3\/C5 convertase of complement by purified human erythrocyte C3b receptor","volume":"50","author":"Daha","year":"1982","journal-title":"Clin Exp Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.3389\/fimmu.2018.02329","article-title":"Unraveling the molecular mechanisms underlying complement dysregulation by nephritic factors in C3G and IC-MPGN","volume":"9","author":"Donadelli","year":"2018","journal-title":"Front Immunol."},{"key":"B30","first-page":"33","article-title":"Stabilization of homologous and heterologous cell-bound amplification convertases, C3bBb, by C3 nephritic factor","volume":"43","author":"Daha","year":"1981","journal-title":"Immunology."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1056\/NEJMc1107484","article-title":"Combined C3b and Factor B autoantibodies and MPGN Type II","volume":"365","author":"Chen","year":"2011","journal-title":"N Engl J Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1681\/ASN.2016030343","article-title":"Anti-factor B and anti-C3b autoantibodies in C3 glomerulopathy and Ig-associated membranoproliferative GN","volume":"28","author":"Marinozzi","year":"2017","journal-title":"J Am Soc Nephrol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/cei.12754","article-title":"Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy","volume":"184","author":"Corvillo","year":"2016","journal-title":"Clin Exp Immunol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/ki.2012.63","article-title":"Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies","volume":"82","author":"Servais","year":"2012","journal-title":"Kidney Int."},{"key":"B35","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.molimm.2016.01.010","article-title":"Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome","volume":"71","author":"Iatropoulos","year":"2016","journal-title":"Mol Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1056\/NEJMra025261","article-title":"Acquired and inherited lipodystrophies","volume":"350","author":"Garg","year":"2004","journal-title":"N Engl J Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.nefro.2017.10.002","article-title":"Acquired partial lipodystrophy and C3 glomerulopathy: dysregulation of the complement system as a common pathogenic mechanism","volume":"38","author":"Corvillo","year":"2018","journal-title":"Nefrologia."},{"key":"B38","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/j.1365-2249.1994.tb06530.x","article-title":"Occurrence of C3 nephritic factor and C4 nephritic factor in membranoproliferative glomerulonephritis (MPGN)","volume":"95","author":"Ohi","year":"1994","journal-title":"Clin Exp Immunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1053\/j.ajkd.2017.07.004","article-title":"C4 Nephritic factors in C3 glomerulopathy: a case series","volume":"70","author":"Zhang","year":"2017","journal-title":"Am J Kidney Dis."},{"key":"B40","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s10875-016-0290-5","article-title":"Testing the activity of complement convertases in serum\/plasma for diagnosis of C4NeF-mediated C3 glomerulonephritis","volume":"36","author":"Blom","year":"2016","journal-title":"J Clin Immunol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1172\/JCI109787","article-title":"Nephritic factor of the classical pathway of complement: immunoglobulin G autoantibody directed against the classical pathway C3 convetase enzyme","volume":"65","author":"Halbwachs","year":"1980","journal-title":"J Clin Invest."},{"key":"B42","first-page":"417","article-title":"Stabilization of the classical pathway C3 convertase C42, by a factor F-42, isolated from serum of patients with systemic lupus erythematosus","volume":"40","author":"Daha","year":"1980","journal-title":"Immunology."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1084\/jem.154.1.1","article-title":"Mechanism of action of the C4 nephritic factor. deregulation of the classical pathway of C3 convertase","volume":"154","author":"Gigli","year":"1981","journal-title":"J Exp Med."},{"key":"B44","first-page":"65","article-title":"C4 nephritic factor in a patient with chronic glomerulonephritis","volume":"22","author":"Fujita","year":"1987","journal-title":"J Clin Lab Immunol."},{"key":"B45","first-page":"82","article-title":"C3 nephritic factor and C4 nephritic factor in the serum of two patients with hypocomplementaemic membranoproliferative glomerulonephritis","volume":"76","author":"Tanuma","year":"1989","journal-title":"Clin Exp Immunol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.clim.2012.09.007","article-title":"Autoantibody stabilization of the classical pathway C3 convertase leading to C3 deficiency and Neisserial sepsis: C4 nephritic factor revisited","volume":"145","author":"Miller","year":"2012","journal-title":"Clin Immunol."},{"key":"B47","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.4049\/jimmunol.125.5.2051","article-title":"Relative resistance of the F-42-stabilized classical pathway C3 convertase to inactivation by C4-binding protein","volume":"125","author":"Daha","year":"1980","journal-title":"J Immunol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/eji.1830141209","article-title":"Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor","volume":"14","author":"Fischer","year":"1984","journal-title":"Eur J Immunol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/cei.12388","article-title":"A novel method for direct measurement of complement convertases activity in human serum: measurement of complement convertases in serum","volume":"178","author":"Blom","year":"2014","journal-title":"Clin Exp Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1080\/08916934.2017.1423286","article-title":"Gain of function mutant of complement factor B K323E mimics pathogenic C3NeF autoantibodies in convertase assays","volume":"51","author":"Urban","year":"2018","journal-title":"Autoimmunity."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.imbio.2016.06.008","article-title":"Complement analysis 2016: clinical indications, laboratory diagnostics and quality control","volume":"221","author":"Proh\u00e1szka","year":"2016","journal-title":"Immunobiology."},{"key":"B52","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1074\/jbc.M410179200","article-title":"Molecular dissection of interactions between components of the alternative pathway of complement and decay accelerating factor (CD55)","volume":"280","author":"Harris","year":"2005","journal-title":"J Biol Chem."},{"key":"B53","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/0022-1759(93)90160-9","article-title":"A novel ELISA assay for the detection of C3 nephritic factor","volume":"159","author":"Seino","year":"1993","journal-title":"J Immunol Methods."},{"key":"B54","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/ki.1979.38","article-title":"Nonimmunoglobulin C3 activating factor in membranoproliferative glomerulonephritis","volume":"15","author":"Bartlow","year":"1979","journal-title":"Kidney Int."},{"key":"B55","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2215\/CJN.07900811","article-title":"Causes of alternative pathway dysregulation in dense deposit disease","volume":"7","author":"Zhang","year":"2012","journal-title":"Clin J Am Soc Nephrol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1093\/ajcp\/76.1.63","article-title":"Test for C3 nephritic factor activity by immunofixation electrophoresis","volume":"76","author":"Koch","year":"1981","journal-title":"Am J Clin Pathol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"31160","DOI":"10.1074\/jbc.274.44.31160","article-title":"Decay accelerating activity of complement receptor type 1 (CD35). two active sites are required for dissociating C5 convertases","volume":"274","author":"Krych-Goldberg","year":"1999","journal-title":"J Biol Chem."},{"key":"B58","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1074\/jbc.M806669200","article-title":"Characterization of the complement inhibitory function of rhesus rhadinovirus complement control protein (RCP)","volume":"284","author":"Okroj","year":"2009","journal-title":"J Biol Chem."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.4049\/jimmunol.166.4.2635","article-title":"Formation of high-affinity C5 convertases of the alternative pathway of complement","volume":"166","author":"Rawal","year":"2001","journal-title":"J Immunol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"16828","DOI":"10.1074\/jbc.273.27.16828","article-title":"C5 convertase of the alternative pathway of complement. kinetic analysis of the free and surface-bound forms of the enzyme","volume":"273","author":"Rawal","year":"1998","journal-title":"J Biol Chem."},{"key":"B61","doi-asserted-by":"publisher","first-page":"e47245","DOI":"10.1371\/journal.pone.0047245","article-title":"Functional analyses of complement convertases using C3 and C5-depleted sera","volume":"7","author":"Okroj","year":"2012","journal-title":"PLoS ONE."},{"key":"B62","doi-asserted-by":"publisher","first-page":"612","DOI":"10.3389\/fimmu.2018.00612","article-title":"Overactivity of alternative pathway convertases in patients with complement-mediated renal diseases","volume":"9","author":"Michels","year":"2018","journal-title":"Front Immunol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/0022-1759(82)90386-6","article-title":"A new screening test for C3 nephritis factor based on a stable cell bound convertase on sheep erythrocytes","volume":"51","author":"Rother","year":"1982","journal-title":"J Immunol Methods."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jim.2007.12.001","article-title":"A hemolytic method for the measurement of nephritic factor","volume":"335","author":"West","year":"2008","journal-title":"J Immunol Methods."},{"key":"B65","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0022-1759(87)90438-8","article-title":"C3 nephritic factor determination. a comparison between two methods","volume":"98","author":"L\u00f3pez-Trascasa","year":"1987","journal-title":"J Immunol Methods."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.3389\/fimmu.2018.01691","article-title":"Functional characterization of alternative and classical pathway C3\/C5 convertase activity and inhibition using purified models","volume":"9","author":"Zwarthoff","year":"2018","journal-title":"Front Immunol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.semnephrol.2011.06.005","article-title":"Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification","volume":"31","author":"Sethi","year":"2011","journal-title":"Semin Nephrol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMra1108178","article-title":"Membranoproliferative glomerulonephritis\u2013a new look at an old entity","volume":"366","author":"Sethi","year":"2012","journal-title":"N Engl J Med."},{"key":"B69","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00467-015-3310-4","article-title":"C3 Glomerulopathy","volume":"32","author":"Riedl","year":"2017","journal-title":"Pediat Nephrol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/nrneph.2010.85","article-title":"C3 glomerulopathy: a new classification","volume":"6","author":"Fakhouri","year":"2010","journal-title":"Nat Rev Nephrol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"248","DOI":"10.12688\/f1000research.10364.1","article-title":"C3 glomerulopathy","volume":"6","author":"Cook","year":"2017","journal-title":"F1000Res."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/ki.2013.377","article-title":"C3 glomerulopathy: consensus report","volume":"84","author":"Pickering","year":"2013","journal-title":"Kidney Int."},{"key":"B73","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.clim.2016.06.001","article-title":"A healthy female with C3 hypocomplementemia and C3 Nephritic Factor","volume":"169","author":"Egan","year":"2016","journal-title":"Clin Immunol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1016\/j.molimm.2011.04.005","article-title":"Dense deposit disease","volume":"48","author":"Smith","year":"2011","journal-title":"Mol Immunol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00467-014-3004-3","article-title":"C3 nephritic factor can be associated with membranous glomerulonephritis","volume":"30","author":"Niel","year":"2015","journal-title":"Pediat Nephrol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1034\/j.1399-3038.2001.012003166.x","article-title":"Complement analysis in children with idiopathic membranoproliferative glomerulonephritis: a long-term follow-up","volume":"12","author":"Schwertz","year":"2001","journal-title":"Pediatr Allergy Immunol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/0002-9343(83)90606-X","article-title":"Idiopathic mesangiocapillary glomerulonephritis. comparison of types I and II in children and adults and long-term prognosis","volume":"74","author":"Cameron","year":"1983","journal-title":"Am J Med."},{"key":"B78","first-page":"240","article-title":"Biological significance of the C3 nephritic factor in membranoproliferative glomerulonephritis","volume":"18","author":"Schena","year":"1982","journal-title":"Clin Nephrol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00467-013-2605-6","article-title":"C3 nephritic factor associated with C3 glomerulopathy in children","volume":"29","author":"Nicolas","year":"2014","journal-title":"Pediat Nephrol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.mayocp.2018.05.019","article-title":"C3 glomerulopathy: ten years' experience at mayo clinic","volume":"93","author":"Ravindran","year":"2018","journal-title":"Mayo Clin Proc."},{"key":"B81","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/0022-1759(90)90468-B","article-title":"Quantitation of C4 nephritic factor by an enzyme-linked immunosorbent assay","volume":"128","author":"Seino","year":"1990","journal-title":"J Immunol Methods."},{"key":"B82","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.ecl.2016.06.012","article-title":"Lipodystrophy syndromes","volume":"45","author":"Hussain","year":"2016","journal-title":"Endocrinol Metab Clin North Am."},{"key":"B83","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1210\/jc.2016-2466","article-title":"The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline","volume":"101","author":"Brown","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"key":"B84","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/01.md.0000111061.69212.59","article-title":"Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature","volume":"83","author":"Misra","year":"2004","journal-title":"Medicine (Baltimore)."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1126\/science.2734615","article-title":"Adipsin and complement factor D activity: an immune-related defect in obesity","volume":"244","author":"Rosen","year":"1989","journal-title":"Science."},{"key":"B86","doi-asserted-by":"crossref","first-page":"9210","DOI":"10.1016\/S0021-9258(19)50409-4","article-title":"Human adipsin is identical to complement factor D and is expressed at high levels in adipose tissue","volume":"267","author":"White","year":"1992","journal-title":"J Biol Chem."},{"key":"B87","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.semcdb.2017.12.017","article-title":"Complement as a diagnostic tool in immunopathology","volume":"85","author":"L\u00f3pez-Lera","year":"2018","journal-title":"Semin Cell Dev Biol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.molimm.2008.09.013","article-title":"Dual role of complement in adipose tissue","volume":"46","author":"Pattrick","year":"2009","journal-title":"Mol Immunol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1056\/NEJM197602262940902","article-title":"The complement abnormalities of lipodystrophy","volume":"294","author":"Sissons","year":"1976","journal-title":"N Engl J Med."},{"key":"B90","first-page":"43","article-title":"Systemic lupus erythematosus, partial lipodystrophy and hypocomplementemia","volume":"6","author":"Jasin","year":"1979","journal-title":"J Rheumatol."},{"key":"B91","first-page":"201","article-title":"C3 nephritic factor in an individual with recurrent viral infection and lipodystrophy","volume":"19","author":"Myers","year":"1986","journal-title":"J Clin Lab Immunol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/S0272-6386(86)80041-5","article-title":"Membranoproliferative glomerulonephritis, type II and partial lipodystrophy in an adult","volume":"8","author":"Pollock","year":"1986","journal-title":"Am J Kidney Dis."},{"key":"B93","first-page":"1083","article-title":"[Barraquer and simons lipodystrophy. complement anomalies and cutaneous leukocytoclasic vasculitis]","volume":"114","author":"Perrot","year":"1987","journal-title":"Ann Dermatol Venereol."},{"key":"B94","first-page":"387","article-title":"Familial incidence of C3 nephritic factor, partial lipodystrophy and membranoproliferative glomerulonephritis","volume":"75","author":"Power","year":"1990","journal-title":"Q J Med."},{"key":"B95","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/0190-9622(90)70042-G","article-title":"Systemic lupus erythematosus in a patient with partial lipodystrophy","volume":"22","author":"Font","year":"1990","journal-title":"J Am Acad Dermatol."},{"key":"B96","first-page":"298","article-title":"Lupus, C3 nephritic factor and partial lipodystrophy","volume":"88","author":"Cronin","year":"1995","journal-title":"QJM."},{"key":"B97","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/j.1365-2230.1996.tb00036.x","article-title":"The clinical significance of partial lipoatrophy and C3 hypocomplementaemia: a report of two cases","volume":"21","author":"Wayte","year":"1996","journal-title":"Clin Exp Dermatol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/0002-9343(77)90879-8","article-title":"Partial lipodystrophy, C3 nephritic factor and clinically inapparent mesangiocapillary glomerulonephritis","volume":"62","author":"Bennett","year":"1977","journal-title":"Am J Med."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1093\/ndt\/12.9.1804","article-title":"Lipodystrophy in MPGN type II: the clue to links between the adipocyte and the complement system","volume":"12","author":"Mathieson","year":"1997","journal-title":"Nephrol Dial Transplant."},{"key":"B100","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/BF02786513","article-title":"Partial lipodystrophy, mesangiocapillary glomerulonephritis, and complement dysregulation. An autoimmune phenomenon","volume":"18","author":"Levy","year":"1998","journal-title":"Immunol Res."},{"key":"B101","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1046\/j.1365-2230.2000.00717.x","article-title":"Partial lipodystrophy and renal disease","volume":"25","author":"Lenane","year":"2000","journal-title":"Clin Exp Dermatol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1681\/ASN.2013070732","article-title":"Characterization of a factor H mutation that perturbs the alternative pathway of complement in a family with membranoproliferative GN","volume":"25","author":"Wong","year":"2014","journal-title":"J Am Soc Nephrol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1007\/s00467-013-2748-5","article-title":"Eculizumab therapy in a patient with dense-deposit disease associated with partial lipodystropy","volume":"29","author":"Ozkaya","year":"2014","journal-title":"Pediat Nephrol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1084\/jem.177.6.1827","article-title":"Complement-mediated adipocyte lysis by nephritic factor sera","volume":"177","author":"Mathieson","year":"1993","journal-title":"J Exp Med."},{"key":"B105","first-page":"609","article-title":"C3 nephritic factor and SLE: report of four cases and review of the literature","volume":"87","author":"Walport","year":"1994","journal-title":"QJM."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1177\/0961203317709347","article-title":"Autoantibodies against complement components in systemic lupus erythematosus - role in the pathogenesis and clinical manifestations","volume":"26","author":"Hristova","year":"2017","journal-title":"Lupus."},{"key":"B107","doi-asserted-by":"crossref","first-page":"821","DOI":"10.4049\/jimmunol.116.3.821","article-title":"Serum factors activating the alternative complement pathway in autoimmune disease: description of two different factors from patients with systemic lupus erythematosus","volume":"116","author":"Arroyave","year":"1976","journal-title":"J Immunol."},{"key":"B108","first-page":"202","article-title":"Modulation of complement by autoimmune antibodies isolated from sera of patients with membranoproliferative glomerulonephritis and systemic lupus erythematosus","volume":"25","author":"Daha","year":"1982","journal-title":"Neth J Med."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1172\/JCI111891","article-title":"A circulating inhibitor of fluid-phase amplification. C3 convertase formation in systemic lupus erythematosus","volume":"75","author":"Waldo","year":"1985","journal-title":"J Clin Invest."},{"key":"B110","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1159\/000234573","article-title":"A factor activating complement via the alternative pathway in the supernatants of B cell lines transformed by Epstein-Barr virus and in sera obtained from patients with systemic lupus erythematosus","volume":"86","author":"Hiramatsu","year":"1988","journal-title":"Int Arch Allergy Appl Immunol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1093\/rheumatology\/34.1.90","article-title":"Hypocomplementaemia, C3 nephritic factor and type III mesangiocapillary glomerulonephritis progressing to systemic lupus erythematosus","volume":"34","author":"Sheeran","year":"1995","journal-title":"Br J Rheumatol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12882-015-0032-6","article-title":"Case report: lupus nephritis with autoantibodies to complement alternative pathway proteins and C3 gene mutation","volume":"16","author":"Nozal","year":"2015","journal-title":"BMC Nephrol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"25343","DOI":"10.1074\/jbc.M115.647008","article-title":"Functional characterization of autoantibodies against complement component C3 in patients with lupus nephritis","volume":"290","author":"Vasilev","year":"2015","journal-title":"J Biol Chem."},{"key":"B114","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2215\/CJN.03990415","article-title":"Relationship of circulating anti-C3b and anti-C1q IgG to lupus nephritis and its flare","volume":"11","author":"Birmingham","year":"2016","journal-title":"Clin J Am Soc Nephrol."},{"key":"B115","first-page":"153","article-title":"Meningococcal meningitis associated with persistent hypocomplementaemia due to circulating C3 nephritic factor","volume":"52","author":"Thompson","year":"1983","journal-title":"Clin Exp Immunol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1056\/NEJM198305123081907","article-title":"Recurrent bacterial infections associated with C3 nephritic factor and hypocomplementemia","volume":"308","author":"Edwards","year":"1983","journal-title":"N Engl J Med."},{"key":"B117","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/j.1365-3083.1984.tb01005.x","article-title":"Factor I deficiency and C3 nephritic factor: immunochemical findings and association with Neisseria meningitidis infection in two patients","volume":"20","author":"Teisner","year":"1984","journal-title":"Scand J Immunol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/j.1699-0463.1984.tb00098.x","article-title":"C3 nephritic factor in a patient with recurrent neisseria meningitidis infections","volume":"92","author":"Teisner","year":"1984","journal-title":"Acta Pathol Microbiol Immunol Scand C."},{"key":"B119","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/j.1365-2362.1987.tb01240.x","article-title":"Bactericidal capacity against neisseria meningitidis of normal human serum and sera with functional deficiencies of the third and eight complement factor","volume":"17","author":"Strate","year":"1987","journal-title":"Eur J Clin Invest."},{"key":"B120","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1159\/000168162","article-title":"Persistent low C3 levels associated with meningococcal meningitis and membranoproliferative glomerulonephritis","volume":"10","author":"Fernandez-Sola","year":"1990","journal-title":"Am J Nephrol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00878356","article-title":"Mesangiocapillary glomerulonephritis associated with meningococcal meningitis, C3 nephritic factor and persistently low complement C3 and C5","volume":"6","author":"Hulton","year":"1992","journal-title":"Pediatr Nephrol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S0022-3476(79)80010-4","article-title":"Idiopathic rapidly progressive glomerulonephritis with C3 nephritic factor and hypocomplementemia","volume":"94","author":"Davis","year":"1979","journal-title":"J Pediatr."},{"key":"B123","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/ki.1984.113","article-title":"C3 metabolism in acute glomerulonephritis: implications for sites of complement activation","volume":"25","author":"Endre","year":"1984","journal-title":"Kidney Int."},{"key":"B124","first-page":"1747","article-title":"Hypocomplementaemia of poststreptococcal acute glomerulonephritis is associated with C3 nephritic factor (C3NeF) IgG autoantibody activity","volume":"9","author":"Fr\u00e9meaux-Bacchi","year":"1994","journal-title":"Nephrol Dial Transplant."},{"key":"B125","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1053\/ajkd.2001.24511","article-title":"Composition of nephritic factor-generated glomerular deposits in membranoproliferative glomerulonephritis type 2","volume":"37","author":"West","year":"2001","journal-title":"Am J Kidney Dis."},{"key":"B126","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.3389\/fimmu.2018.02237","article-title":"Interpretation of serological complement biomarkers in disease","volume":"9","author":"Ekdahl","year":"2018","journal-title":"Front Immunol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.molimm.2012.05.009","article-title":"Factor H autoantibodies in membranoproliferative glomerulonephritis","volume":"52","author":"Goodship","year":"2012","journal-title":"Mol Immunol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nrneph.2016.99","article-title":"Anti-complement-factor H-associated glomerulopathies","volume":"12","author":"Durey","year":"2016","journal-title":"Nat Rev Nephrol."},{"key":"B129","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.molimm.2010.02.002","article-title":"Anti-factor B autoantibody in dense deposit disease","volume":"47","author":"Strobel","year":"2010","journal-title":"Mol Immunol."},{"key":"B130","doi-asserted-by":"publisher","first-page":"5129","DOI":"10.4049\/jimmunol.1402770","article-title":"Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases","volume":"194","author":"Blanc","year":"2015","journal-title":"J Immunol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/ki.1986.278","article-title":"H deficiency in two brothers with atypical dense intramembranous deposit disease","volume":"30","author":"Levy","year":"1986","journal-title":"Kidney Int."},{"key":"B132","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1097\/01.ASN.0000115702.28859.A7","article-title":"Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases","volume":"15","author":"Dragon-Durey","year":"2004","journal-title":"J Am Soc Nephrol."},{"key":"B133","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/sj.ki.5000269","article-title":"Deletion of Lys224 in regulatory domain 4 of factor H reveals a novel pathomechanism for dense deposit disease (MPGN II)","volume":"70","author":"Licht","year":"2006","journal-title":"Kidney Int."},{"key":"B134","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1681\/ASN.2015040348","article-title":"A familial C3GN secondary to defective C3 regulation by complement receptor 1 and complement factor H","volume":"27","author":"Chauvet","year":"2016","journal-title":"J Am Soc Nephrol."},{"key":"B135","doi-asserted-by":"publisher","first-page":"3702","DOI":"10.1172\/JCI43343","article-title":"Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation","volume":"120","author":"Mart\u00ednez-Barricarte","year":"2010","journal-title":"J Clin Invest."},{"key":"B136","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1093\/ndt\/gfv054","article-title":"Familial C3 glomerulonephritis associated with mutations in the gene for complement factor B","volume":"30","author":"Imamura","year":"2015","journal-title":"Nephrol Dial Transplant."},{"key":"B137","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/S0140-6736(10)60670-8","article-title":"Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis","volume":"376","author":"Gale","year":"2010","journal-title":"Lancet."},{"key":"B138","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/ki.2013.348","article-title":"A novel CFHR5 fusion protein causes C3 glomerulopathy in a family without Cypriot ancestry","volume":"85","author":"Medjeral-Thomas","year":"2014","journal-title":"Kidney Int."},{"key":"B139","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1681\/ASN.2012020166","article-title":"A hybrid CFHR3-1 gene causes familial C3 glomerulopathy","volume":"23","author":"Malik","year":"2012","journal-title":"J Am Soc Nephrol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"4685","DOI":"10.1073\/pnas.1219260110","article-title":"Dimerization of complement factor H-related proteins modulates complement activation in vivo","volume":"110","author":"Goicoechea de Jorge","year":"2013","journal-title":"Proc Natl Acad Sci USA."},{"key":"B141","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1172\/JCI68280","article-title":"C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation","volume":"123","author":"Tortajada","year":"2013","journal-title":"J Clin Invest."},{"key":"B142","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1172\/JCI71866","article-title":"Complement factor H-related hybrid protein deregulates complement in dense deposit disease","volume":"124","author":"Chen","year":"2014","journal-title":"J Clin Invest."},{"key":"B143","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.molimm.2016.07.007","article-title":"Familial C3 glomerulonephritis caused by a novel CFHR5-CFHR2 fusion gene","volume":"77","author":"Xiao","year":"2016","journal-title":"Mol Immunol."},{"key":"B144","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1007\/s00467-015-3111-9","article-title":"Successful therapy of C3Nef-positive C3 glomerulopathy with plasma therapy and immunosuppression","volume":"30","author":"H\u00e4ffner","year":"2015","journal-title":"Pediatr Nephrol."},{"key":"B145","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/jca.10026","article-title":"Management of membranoproliferative glomerulonephritis type II with plasmapheresis","volume":"17","author":"Kurtz","year":"2002","journal-title":"J Clin Apher."},{"key":"B146","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1159\/000187889","article-title":"Immunosuppressive treatment of membranoproliferative glomerulonephritis","volume":"67","author":"Faedda","year":"1994","journal-title":"Nephron."},{"key":"B147","first-page":"234","article-title":"Comparison of pulse and oral steroid in childhood membranoproliferative glomerulonephritis","volume":"20","author":"Bahat","year":"2007","journal-title":"J Nephrol."},{"key":"B148","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1038\/ki.2015.227","article-title":"Effectiveness of mycophenolate mofetil in C3 glomerulonephritis","volume":"88","author":"Rabasco","year":"2015","journal-title":"Kidney Int."},{"key":"B149","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s00467-015-3061-2","article-title":"A case of C3 glomerulonephritis successfully treated with eculizumab","volume":"30","author":"Payette","year":"2015","journal-title":"Pediat Nephrol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"57","DOI":"10.5414\/CN107945","article-title":"Remission of C3 glomerulopathy with rituximab as only immunosuppressive therapy","volume":"83","author":"Giaime","year":"2015","journal-title":"Clin Nephrol."},{"key":"B151","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s00467-013-2711-5","article-title":"Rituximab fails where eculizumab restores renal function in C3nef-related DDD","volume":"29","author":"Rousset-Rouvi\u00e8re","year":"2014","journal-title":"Pediatr Nephrol."},{"key":"B152","doi-asserted-by":"publisher","first-page":"2180508","DOI":"10.1155\/2017\/2180508","article-title":"Rituximab for treatment of membranoproliferative glomerulonephritis and C3 glomerulopathies","volume":"2017","author":"Rudnicki","year":"2017","journal-title":"Biomed Res Int."},{"key":"B153","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1055\/s-0034-1375299","article-title":"Treatment of C3 glomerulopathy with complement blockers","volume":"40","author":"Vivarelli","year":"2014","journal-title":"Semin Thromb Hemost."},{"key":"B154","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2017.11.019","article-title":"Patterns of clinical response to eculizumab in patients with C3 glomerulopathy","volume":"72","author":"Le Quintrec","year":"2018","journal-title":"Am J Kidney Dis."},{"key":"B155","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1681\/ASN.2013010045","article-title":"Soluble CR1 therapy improves complement regulation in C3 glomerulopathy","volume":"24","author":"Zhang","year":"2013","journal-title":"J Am Soc Nephrol."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.00886\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T23:56:06Z","timestamp":1694822166000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.00886\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,24]]},"references-count":155,"alternative-id":["10.3389\/fimmu.2019.00886"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.00886","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,24]]},"article-number":"886"}}